NCT07761416

Brief Summary

Ovarian cancer is a deadly disease that is hard to detect early and difficult to treat. Research shows that most ovarian cancers actually start in the fallopian tubes, not the ovaries. Removing the fallopian tubes (a procedure called salpingectomy) can lower the risk of ovarian cancer by about 80%. This procedure has no added risk to the patient, but does lead to sterilization and thus it is only offered to individuals who have completed child-bearing. Adding salpingectomy to another surgery that a patient is undergoing is called opportunistic salpingectomy and is already standard of practice in many gynecologic surgeries, such as hysterectomy. However, it is not yet commonly offered during weight-loss (bariatric) surgery, even though many patients having this surgery could benefit. This study will test whether it is practical and safe to offer fallopian tube removal during bariatric surgery at three hospitals in Canada. Patients who are eligible and interested will be invited to have their fallopian tubes removed at the same time as their planned weight-loss surgery. The research team will track whether the procedure can be completed successfully, whether there are any added complications, and how much extra time or resources are needed. The goal is to help make this cancer-prevention option available to more people.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P50-P75 for early_phase_1 ovarian-cancer

Timeline
8mo left

Started Aug 2026

Shorter than P25 for early_phase_1 ovarian-cancer

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Aug 2026Mar 2027

Study Start

First participant enrolled

August 1, 2026

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

August 3, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 12, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2027

Last Updated

August 12, 2026

Status Verified

August 1, 2026

Enrollment Period

5 months

First QC Date

August 3, 2026

Last Update Submit

August 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of participants that successfully undergo opportunistic salpingectomy at time of their bariatric surgery

    From study commencement for 6 months

Secondary Outcomes (8)

  • Length of hospital stay

    Length in days from admission to discharge from hospital, assessed up to 100 days

  • 30-day hospital readmission rate

    From procedure end to 30 days postoperatively

  • Blood transfusion

    From procedure start to 30 days postoperatively

  • Surgical site infection

    From procedure end to 30 days postoperatively

  • Additional OR time required

    From start of salpingectomy to end of salpingectomy, assessed up to 10 hours

  • +3 more secondary outcomes

Study Arms (1)

Opportunistic salpingectomy at bariatric surgery

EXPERIMENTAL

Addition of opportunistic salpingectomy to planned elective bariatric surgery

Procedure: Opportunistic salpingectomy at time of bariatric surgery

Interventions

Opportunistic salpingectomy (fallopian tube removal) at time of planned elective bariatric surgery

Opportunistic salpingectomy at bariatric surgery

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals with fallopian tubes (no prior salpingectomy/salpingo-oophorectomy) who are undergoing an elective MBS and have completed child-bearing

You may not qualify if:

  • unable to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 3, 2026

First Posted

August 12, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

March 30, 2027

Last Updated

August 12, 2026

Record last verified: 2026-08